XML 26 R11.htm IDEA: XBRL DOCUMENT
v3.19.2

GOODWILL AND OTHER INTANGIBLE ASSETS | 6 Months Ended
--- | ---
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Changes in the carrying amount of goodwill for the six-month period ended June 30, 2019 were as follows:
| Codman Specialty Surgical |  | Orthopedics and Tissue Technologies |  | Total
| (In thousands)
Goodwill at December 31, 2018 | $ | 625,760 |  |  | $ | 300,715 |  |  | $ | 926,475 |
Foreign currency translation | 174 |  |  | 83 |  |  | 257 |
Goodwill at June 30, 2019 | $ | 625,934 |  |  | $ | 300,798 |  |  | $ | 926,732 |
The components of the Company’s identifiable intangible assets were as follows:
| June 30, 2019
| Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
| (Dollars in thousands)
Completed technology | 19 years |  | $ | 856,730 |  |  | $ | (190,219 | ) |  | $ | 666,511 |
Customer relationships | 13 years |  | 222,784 |  |  | (111,617 | ) |  | 111,167 |
Trademarks/brand names | 28 years |  | 104,041 |  |  | (26,688 | ) |  | 77,353 |
Codman trade name | Indefinite |  | 162,466 |  |  | — |  |  | 162,466 |
Supplier relationships | 27 years |  | 34,721 |  |  | (17,233 | ) |  | 17,488 |
All other | 4 years |  | 10,913 |  |  | (4,278 | ) |  | 6,635 |
|  |  | $ | 1,391,655 |  |  | $ | (350,035 | ) |  | $ | 1,041,620 |
| December 31, 2018
| Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
| (Dollars in thousands)
Completed technology | 19 years |  | $ | 855,679 |  |  | $ | (167,384 | ) |  | $ | 688,295 |
Customer relationships | 13 years |  | 231,448 |  |  | (106,859 | ) |  | 124,589 |
Trademarks/brand names | 28 years |  | 104,061 |  |  | (24,764 | ) |  | 79,297 |
Codman trade name | Indefinite |  | 162,054 |  |  | — |  |  | 162,054 |
Supplier relationships | 27 years |  | 34,721 |  |  | (16,519 | ) |  | 18,202 |
All other | 4 years |  | 10,958 |  |  | (3,899 | ) |  | 7,059 |
|  |  | $ | 1,398,921 |  |  | $ | (319,425 | ) |  | $ | 1,079,496 |
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately $32.6 million for the remainder of 2019, $65.2 million in 2020, $64.1 million in 2021, $60.6 million in 2022, $59.8 million in 2023, $58.9 million in 2024 and $535.6 million thereafter. In April 2019, a contract manufacturing customer of our Private Label product line received a notification from the FDA ordering them to remove their product from the market. During the second quarter of 2019, the Company recorded an impairment charge of $5.8 million in intangible asset amortization in the consolidated statement of operations related to the customer relationship intangible asset acquired from TEI Biosciences, Inc. and TEI Medical Inc. (collectively "TEI") due to revised future projections based on a pending contract termination.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration